These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity. Schmid DM; Roy S; Sulser T; Scheiner D BJU Int; 2008 Jul; 102 Suppl 1():7-10. PubMed ID: 18665972 [TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin A for the Treatment of Overactive Bladder. Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559 [TBL] [Abstract][Full Text] [Related]
6. The case for bladder botulinum toxin application. Kim DK; Thomas CA; Smith C; Chancellor MB Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386 [TBL] [Abstract][Full Text] [Related]
7. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Kuo HC; Liao CH; Chung SD Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type A for the treatment of lower urinary tract disorders. Yokoyama T; Chancellor MB; Oguma K; Yamamoto Y; Suzuki T; Kumon H; Nagai A Int J Urol; 2012 Mar; 19(3):202-15. PubMed ID: 22220916 [TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely. Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677 [TBL] [Abstract][Full Text] [Related]
10. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity. King AB; Rapp DE Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656 [TBL] [Abstract][Full Text] [Related]
11. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it? da Silva CM; Cruz F Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121 [TBL] [Abstract][Full Text] [Related]
12. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance? Pistolesi D; Giannarini G; Stampacchia G; Selli C Eur Urol; 2011 Oct; 60(4):872-3. PubMed ID: 21802198 [No Abstract] [Full Text] [Related]
13. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Patel AK; Patterson JM; Chapple CR Eur Urol; 2006 Oct; 50(4):684-709; discussion 709-10. PubMed ID: 16934391 [TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults. Tincello DG World J Urol; 2012 Aug; 30(4):451-6. PubMed ID: 22002834 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149 [TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin injection therapy in the management of lower urinary tract dysfunction. Patel AK; Chapple CR Int J Clin Pract Suppl; 2006 Dec; (151):1-7. PubMed ID: 17169004 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). Mohee A; Khan A; Harris N; Eardley I BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569 [TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. Dressler D; Bigalke H; Benecke R J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917 [TBL] [Abstract][Full Text] [Related]
20. Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. Charrua A; Avelino A; Cruz F Handb Exp Pharmacol; 2011; (202):345-74. PubMed ID: 21290235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]